Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,615
datasets available to search
ShareScore release 0.9.0
Dataset results
1,615 results for “tumour”
Processed CODEX Datasets from - Graph deep learning for the characterization of tumour microenvironments from spatial protein profiles in tissue specimens
<p>This entry provides access to processed CODEX data files of three studies analyzed in the article "Graph deep learning for the characterization of tumour microenvironments from spatial protein profiles in tissue specimens". Details of datasets can be found in the Methods section of the article.</p> <p>For each dataset:</p> <ul> <li>A comma-separated values (CSV) file containing metadata of regions is included</li> <li>A zip file containing multiple CSV files is included: <ul> <li>`{region_id}.cell_data.csv`, a table containing three columns: "CELL_ID", "X", and "Y". This table provides centroid locations for all cells segmented in this region.</li> <li>`{region_id}.expression.csv`, a table containing multiple columns: "CELL_ID", "DAPI", "CD45", etc. This table provides detailed protein biomarker expression quantified and normalized for all cells in this region.</li> <li>`{region_id}.cell_types.csv`, a table containing two columns: "CELL_ID" and "CELL_TYPE". This table provides cell type annotations for all cells in this region.</li> <li>`{region_id}.cell_features.csv`, a table containing two columns: "CELL_ID" and "SIZE". This table provides morphology descriptors (only containing cell size for these studies) for all cells in this region.</li> </ul> </li> </ul> <p>These data files are also available through the Enable Medicine Public Study page: <a href="https://app.enablemedicine.com/portal/atlas-library/studies/92394a9f-6b48-4897-87de-999614952d94?sid=1168">https://app.enablemedicine.com/portal/atlas-library/studies/92394a9f-6b48-4897-87de-999614952d94?sid=1168</a>. Raw multiplexed immunofluorescence images will be accessible through the visualizer app of Enable Medicine Portal.</p> <p>Codes for this study are stored in <a href="https://gitlab.com/enable-medicine-public/space-gm">https://gitlab.com/enable-medicine-public/space-gm</a>. Please direct all further questions and/or issues to the gitlab repository or lead contact (A.E.T.).</p>
Data from: Sex bias in ability to cope with cancer: Tasmanian devils and facial tumour disease.
Knowledge of the ecological dynamics between hosts and pathogens during the initial stages of disease emergence is crucial to understanding the potential for evolution of new interspecific interactions. Tasmanian devil (Sarcophilus harrisii) populations have declined precipitously owing to infection by a transmissible cancer (devil facial tumour disease, DFTD) that emerged approximately 20 years ago. Since the emergence of DFTD, and as the disease spreads across Tasmania, the number of devil has dropped up to 90% across 80% of the species' distributional range. As a result, the disease is expected to act as a strong selective force on hosts to develop mechanisms of tolerance and/or resistance to the infection. We assessed the ability of infected devils to cope with infection, which translates into host tolerance to the cancer, by using the reaction norm of the individual body condition by tumour burden. We found that body condition of infected hosts is negatively affected by cancer progression. Males and females presented significant differences in their tolerance levels to infection, with males suffering declines of up to 25% of their body condition, in contrast to <5% in females. Sex-related differences in tolerance to cancer progression may select for changes in life history strategies of the host and could also alter the selective environment for the tumours.
Extended figures: Tumour immune rejection triggered by activation of alpha2-adrenergic receptors
<p>Code and data to reproduce the extended figures from Tumour immune rejection triggered by activation of alpha2-adrenergic receptors by Zhu et al. </p>
Dataset: Automated quantification of stromal tumour infiltrating lymphocytes is associated with prognosis in breast cancer.
<p>Daraset of breast nulcei segmentation associated to the article "Gonzàlez-Farré, M., Gibert, J., Santiago-Díaz, P. <em>et al.</em> Automated quantification of stromal tumour infiltrating lymphocytes is associated with prognosis in breast cancer. <em>Virchows Arch</em> (2023). https://doi.org/10.1007/s00428-023-03608-4"</p>
The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.
ClinicalTrials.gov study NCT02430311. IPD Sharing: Not stated. Countries: 1. Publications: 1.
RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours
ClinicalTrials.gov study NCT03199872. IPD Sharing: NO. Countries: 1. Publications: 1.
Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer
ClinicalTrials.gov study NCT00259090. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study to Test the Efficacy of the Vaccine GSK 249553 in Treating Non-small-cell Lung Cancer After Tumour Removal by Surgery
ClinicalTrials.gov study NCT00290355. IPD Sharing: YES. Countries: 14. Publications: 3.
BI 6727 (Volasertib) Monotherapy Phase I Trial in Japanese Patients With Advanced Solid Tumours
ClinicalTrials.gov study NCT01348347. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney Function
ClinicalTrials.gov study NCT01894256. IPD Sharing: Not stated. Countries: 5. Publications: 1.
Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours
ClinicalTrials.gov study NCT02094261. IPD Sharing: YES. Countries: 8. Publications: 5.
Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients
ClinicalTrials.gov study NCT02075606. IPD Sharing: Not stated. Countries: 1. Publications: 2.
To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
ClinicalTrials.gov study NCT03220217. IPD Sharing: Not stated. Countries: 3. Publications: 1.
BIBW 2992 (Afatinib) in Combination With Pemetrexed in Advanced Solid Tumours
ClinicalTrials.gov study NCT01169675. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.
ClinicalTrials.gov study NCT00998296. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Targeted Chemotherapy Using Focused Ultrasound for Liver Tumours
ClinicalTrials.gov study NCT02181075. IPD Sharing: NO. Countries: 1. Publications: 4.
An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 (Volasertib)in Combination With Oral BIBW 2992 (Afatinib) in Patients With Advanced Solid Tumours
ClinicalTrials.gov study NCT01206816. IPD Sharing: Not stated. Countries: 1. Publications: 1.
111In-ch806 in Patients With Advanced Tumours Expressing the 806 Antigen
ClinicalTrials.gov study NCT00291447. IPD Sharing: NO. Countries: 1. Publications: 1.
A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours
ClinicalTrials.gov study NCT02402062. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
ClinicalTrials.gov study NCT03166631. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.